To ensure that this reaction was not purely rodent-based, the scientists also checked the blood taken from the elderly. Older men and women who habitually walked for exercise exhibited higher levels of GPLD1 in their blood flows than those who did not.
The joint result of these findings appears to be that exercise improves brain health in part by prompting the liver to pump extra amounts of GPLD1, says dr. Villeda, although it is not yet clear how the protein then changes the brain. Subsequent experiments conducted by scientists have shown that the protein probably does not violate the blood brain barrier and does not act directly on the brain, says Dr. Villeda. Instead, it is likely to incite alterations in other tissues and cells in other parts of the body. These tissues, in turn, produce even more proteins that have effects on other tissues which ultimately lead to direct changes to neurotransmitters, genes and brain cells that undergo cognitive enhancements.
Dr. Villeda believes that if further experiments show that GPLD1, in isolation, helps initiate this molecular chain reaction, it is at least conceivable that infusions of the substance may offer the brain benefits of exercise to people who are too fragile or disabled to regulate. physical activity.
This experiment mainly involved mice, but not people, and tells us nothing about the systemic effects of extra GPLD1, which in high quantities may be undesirable. More fundamentally, the results highlight the pervasive, intricate effects of the whole body of the exercise, with the liver, in this case, which somehow changes mind and brain after training. At the moment, it is impossible to know if all the same synchronized and intertwined processes would all occur in response to a GPLD1 exercise pill and, if not, if it could be considered an exercise pill.
Dr. Villeda quickly agrees that pharmaceutical GPLD1, while effective for brain health, “would not recapitulate the benefits of exercise.” There would be none of the usual fat burners, muscle building or cardiovascular improvements, he points out. But he hopes that if future experiments in his laboratory with animals and people show consistent results, the substance could eventually help people who have difficulty moving better to think better.